Regentis Biomaterials Ltd. (RGNT) is a publicly traded the market company. As of July 26, 2026, RGNT trades at $1.93 with a market cap of $13.77M and a P/E ratio of 0.00. RGNT moved +0.51% today. Year to date, RGNT is -70.53%; over the trailing twelve months it is flat. Its 52-week range spans $1.23 to $15.50. Rallies surfaces RGNT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Regentis Biomaterials Raises $6.5M via $3.50 Share Private Placement with $4.20 Warrants: Regentis Biomaterials priced a $6.5 million private placement of 1,857,143 shares (or pre-funded warrants) at $3.50 each alongside warrants exercisable at $4.20, expected to close June 23. Proceeds will support the pivotal GelrinC U.S. trial, FDA pre-market approval preparation, manufacturing scale-up, European market entry and working capital.
| Metric | Value |
|---|---|
| Price | $1.93 |
| Market Cap | $13.77M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.50 |
| 52-Week Low | $1.23 |
| Volume | 68.67K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
RGNT analyst coverage data. Average price target: $0.00.